Show simple item record

dc.contributor.authorThomas, A. L.en
dc.contributor.authorByrne, Ken
dc.contributor.authorFurber, L.en
dc.contributor.authorSteward, W. P. S.en
dc.date.accessioned2016-03-31T10:49:49Z
dc.date.available2016-03-31T10:49:49Z
dc.date.issued2001-10
dc.identifier.citationThomas, A.L, Byrne, K., Furber, L. and Steward, W.P.S. (2001) A phase II study of Caelyx, liposomal doxorubicin: Lack of activity in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 48 (4). pp. 266-268en
dc.identifier.otherPMID: 11710625
dc.identifier.urihttp://hdl.handle.net/2086/11749
dc.description.abstractPURPOSE: A phase II study was designed to assess the efficacy and safety of Caelyx (liposomal doxorubicin) in patients with advanced or metastatic gastric cancer. METHODS: A total of 25 patients with gastric adenocarcinoma were treated with Caelyx 45 mg/m2 every 28 days as first-line therapy for advanced disease. Patients were treated until tumour progression or unacceptable toxicity. RESULTS: One patient was withdrawn from the study after experiencing a severe infusion reaction. Of the 24 evaluable patients, 1 had a partial response, 7 had stable disease and the others progressed. Side effects, in particular palmar-plantar erythrodysaesthesia and haematological toxicity, were minor. CONCLUSIONS: We conclude that while this dose and schedule of Caelyx in this patient group is acceptable, further studies with this regimen cannot be recommended due to the lack of antitumour activity seen.en
dc.language.isoenen
dc.publisherCancer Chemotherapy and Pharmacologyen
dc.titleA phase II study of Caelyx, liposomal doxorubicin: Lack of activity in patients with advanced gastric cancer.en
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.1007/s002800100351
dc.peerreviewedYesen
dc.fundern/aen
dc.projectidn/aen
dc.cclicenceN/Aen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record